Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state

Thrombosis and Haemostasis

Volumn 95, Issue 1, 2006, Pages 94-99

  Pereira, Jaime ^a   Alfaro, Gino ^a   Goycoolea, Manuela ^a   Quiroga, Teresa ^a   Ocqueteau, Mauricio ^a   Massardo, Loreto ^a   Pérez, Carol ^a   Sáez, Claudia ^a   Panes, Olga ^a   Matus, Valeria ^a   Mezzano, Diego ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Microparticles; Systemic lupus erythematosus; Thrombin generation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIPLASMIN; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; LIPOCORTIN 5; LUPUS ANTICOAGULANT; MONOCLONAL ANTIBODY; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PROCOAGULANT; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

ADOLESCENT; ADULT; AGED; ANTIGENICITY; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME SYNTHESIS; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTIPLASMIN; ANTITHROMBIN III; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELETS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PLASMIN; PLATELET COUNT; THROMBIN;

EID: 33645551730     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-05-0310     Document Type: Article

References (49)

1. Ruiz-Irastorza G et al. Systemic lupus erythematosus. Lancet 2001; 357: 1027-32.
2. Salmon JE, Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: implication for patient management. Curr Opin Rheumatol 2001; 13: 341-4.
3. Manzi S et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15.
4. Esdaile JM et al. Traditional Framingham risk factors fails to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7.
5. Fitzgerald DJ et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
6. Furman MI et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31: 352-8.
7. Huo Y et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-7.
8. Pasquet JM et al. Procoagulant activity and active calpain in platelet-derived microparticles. Blood 1996; 82: 509-22.
9. Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phopholipid asymmetry in blood cells. Blood 1997; 89: 1121-32.
10. Müller I et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17: 476-8.
11. Biró E et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003; 1: 2561-8.
12. VanWijk MJ et al. Microparticles in cardiovascular diseases. Cardiovasc Res 2003; 59: 277-87.
13. Warkentin TE et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
14. Combes V et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93-102.
15. Mallat Z et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-3.
16. Bretelle F et al. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 2003; 89: 486-92.
17. Nagahama M et al. Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus. Autoimmunity 2001; 33: 85-94.
18. Joseph JE et al. Increased circulating platelet-leukocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115: 451-9.
19. Knijff-Dutmar EAJ et al. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002; 46: 1498-503.
20. Abid Hussein MN et al. Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J Thromb Haemost 2003; 1: 2434-43.
21. Ekdahl KN et al. Thrombotic disease in systemic lupus erythematosus is associated with maintained systemic platelet activation. Br J Haematol 2004; 125: 74-8.
22. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25; 1271-7.
23. Guzmán J et al. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551-8.
24. Shet AS et al. Sickle blood contains tissue factor-positive microparticles dereived from endothelial cells and monocytes. Blood 2003; 102: 2678-83.
25. Quiroga T et al. Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages. Pathophysiol Haemost Thromb 2003; 33: 30-5.
26. Hemker HC et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
27. Brandt JT et al. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for the identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipids Antibodies of the ISTH. Thromb Haemost 1995; 74: 1597-603.
28. Sims PJ et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. J Biol Chem 1989; 264: 17049-57.
29. Zwaal RFA et al. Platelet procoagulant activity and microvesicle formation: its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1992; 1180: 1-8.
30. Dorsch C, Meyerhoff J. Elevated plasma beta-thromboglobulin levels in systemic lupus erythematosus. Thromb Res 1980; 20: 617-22.
31. Ekdahl KN et al. Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus: covariation with platelet activation and possible association with thrombosis. Arthritis Rheum 1997; 40: 2178-86.
32. Desai-Mehta A et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-73.
33. Koshy M et al. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 826-37.
34. Inwald DP et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Cir Res 2003; 92: 1041-8.
35. Danese S et al. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release : a novel pathway for immune response amplification. J Immunol 2004; 172: 2010-15.
36. Vanags DM et al. Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Br J Haematol 1997; 99: 824-31.
37. Wolf BB et al. Calpain functions in a caspase-independent manner to promote apoptosis- like events during platelet activation. Blood 1999; 94: 1683-92.
38. Brown SB et al. Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis. A caspase-independent cell clearance program. J Biol Chem 2000; 275: 5987-96.
39. Li J et al. The mechanism of apoptosis in human platelets during storage. Transfusion 2000; 40: 1320-9.
40. Klint C, Truedsson L, Andreasson A et al. Toxic effects of SLE serum on normal monocytes in vitro: cell death induced by apoptosis related to complement dysfunction. Lupus 2000; 9: 278-87.
41. Bengtsson AA et al. Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus- an additional mechanism to increased autoantigen load?. Clin Exp Immunol 2004; 135: 535-43.
42. Rajagopalan S et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004; 103: 3677-83.
43. Gilbert GE et al. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 1991; 266: 17261-8.
44. Wiedmer T et al. Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry 1990; 29: 623-32.
45. Joop K et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001; 85: 810-20.
46. Sturk-Maquelin KN et al. Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 2003; 1: 1920-6.
47. Hemker HC et al. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2004; 11: 170-5.
48. Dignat-George F et al. Endothelial microparticles: a potential contribution to the thrombotic complications of antiphospholipid syndrome. Thromb Haemost 2004; 91: 667-73.
49. De Prost D et al. Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus. Thromb Haemost 1990; 64: 216-21.